Holen Sie sich die Stockscreener-App
32.92
0.84%
-0.28
Handel nachbörslich:
32.92
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3%Here's Why - MarketBeat
TANG CAPITAL MANAGEMENT LLC Expands Stake in LENZ Therapeutics I - GuruFocus.com
Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - The Malaysian Reserve
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year HighWhat's Next? - MarketBeat
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at 4 Major Healthcare Investor Conferences | LENZ Stock News - StockTitan
Leerink Partnrs Issues Optimistic Estimate for LENZ Earnings - MarketBeat
LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World
Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
FY2024 EPS Estimate for LENZ Therapeutics Boosted by Analyst - MarketBeat
William Blair Has Bullish Outlook for LENZ FY2024 Earnings - MarketBeat
Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks
LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com UK
Form 424B3 LENZ Therapeutics, Inc. - StreetInsider.com
LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Employ Inc. Announces Promotion of Stephanie Manzelli to Chief Human Resources Officer - The Manila Times
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Registration Open for CME/CE-Accredited Free Event Nov 7 - InvisionMag
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 - The Manila Times
LENZ Therapeutics Insider Buyers See Boost After Market Cap Rose US$97m - Simply Wall St
Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter
LENZ reports positive Chinese study data for far-sightedness drug - MSN
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships - AOL
Wescott Financial Advisory Group LLC Acquires 2,154 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - ForexTV.com
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial - The Bakersfield Californian
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Price Target from Analysts - MarketBeat
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance
Mcf Energy Ltd (MCF-X) QuotePress Release - The Globe and Mail
LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - Marketscreener.com
Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga
One new option listing and ten option delistings on October 21st - TipRanks
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - Marketscreener.com
Behind the Bell: LENZ Therapeutics - Nasdaq
FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs - MarketBeat
Presbyopia Market on Track for Major Expansion by 2034, - openPR
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc. - Yahoo Finance
Lenz Co. stock soars to 52-week high, hits $26.18 By Investing.com - Investing.com Canada
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Yahoo Finance
TJX Companies (TJX-N) QuotePress Release - The Globe and Mail
Dimensional Fund Advisors LP Increases Holdings in Koss Co. (NASDAQ:KOSS) - Defense World
Creative Planning Buys 296 Shares of PVH Corp. (NYSE:PVH) - Defense World
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Increase in Short Interest - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Neumora Therapeutics executive sells over $200k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics executive sells over $200k in company stock - Investing.com India
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 5,563 Shares - MarketBeat
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):